Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digoxin + azacitidine + venetoclax in newly diagnosed elderly acute myeloid leukemia
ChiCTR2600131877Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of digoxin, azacitidine and venetoclax in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: 3/6-month CR/CRi and Maximum tolerated dose. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
digoxinazacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600131877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131877.